Clinicopathological significance of stromal variables: Angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Sun, Xiao Feng ^a   Zhang, Hong ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANTIBODY; BEVACIZUMAB; CELL PROTEIN; CETUXIMAB; CGS 27023A; CYTOTOXIC AGENT; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IMC 1C11; IRINOTECAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MP 1270; MPI 270; OXALIPLATIN; PANITUMUMAB; PARTICULARLY INTERESTING NEW CYSTEINE HISTIDINE RICH PROTEIN; PRINOMASTAT; PROTEIN; REBIMASTAT; SORAFENIB; SUNITINIB; TANOMASTAT; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANGIOGENESIS; BLOOD VESSEL; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER RESEARCH; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CARCINOMA; EPITHELIUM; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INFLAMMATORY INFILTRATE; LYMPH VESSEL; LYMPHANGIOGENESIS; MUSCULOSKELETAL DISEASE; NONHUMAN; ONCOGENE; PHENOTYPE; REVIEW; STROMA; STROMA CELL; TISSUE INTERACTION; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HUMANS; INFLAMMATION; LIM DOMAIN PROTEINS; LYMPHANGIOGENESIS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS;

EID: 33750448006     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-43     Document Type: Review

References (220)

1. Sappino AP, Schurch W, Gabbiani G: Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990, 63:144-161.
2. van den Hooff A: Stromal involvement in malignant growth. Adv Cancer Res 1988, 50:159-96.
3. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marme D: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005, 16:558-565.
4. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
5. Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR: A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 2005, 16:997-1002.
6. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H. LoBuglio AF: A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-ICII, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003 9:1323-1232.
7. Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E. Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H: A phase I study of oral BMS-275291 a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004, 10:1963-1970.
8. Noël A, Gilles C, Bajou K, Devy L, Kebers F, Lewalle JM, Maquoi E, Munaut C, Remacle A, Foidart JM: Emerging roles for proteinases in cancer. Invasion Metastasis 1997, 17:221-239.
9. Sivridis E, Giatromanolaki A, Koukourakis MI: "Stromatogenesis" and tumor progression. Int J Surg Pathol 2004, 12:1-9.
10. Giatromanolaki A, Sivridis E, Koukourakis MI: Tumour angiogenesis: vascular growth and survival. APMIS 2004, 112:431-440.
11. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82:4-6.
12. Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, Tachibana T, Imamura M: Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005, 69:159-166.
13. Björndahl M: Lymphanginogenesis and lymphatic metastasis. Swedish PhD thesis 2005. ISBN: 91-7140-562-3.
14. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, O'Dwyer ST, Jayson GC: Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 2003, 89:426-430.
15. Leak LV, Burke JF: Fine structure of the lymphatic capillary and the adjoining connective tissue area. Am J Anat 1966, 118:785-809.
16. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A: Vascular endothelial growth factor receptor-I modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001, 159:993-1008.
17. Bergsland EK: Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm 2004, 61:S4-11.
18. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001, 20:4762-4773.
19. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RI: VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001, 3:420-427.
20. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB: The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003, 200:183-189.
21. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K: Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 2004, 95:32-39.
22. Parr C, Jiang WG: Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int J Oncol 2003, 23:533-539.
23. Witmer AN, van Blijswijk BC, Dai J, Hofman P, Partanen TA, Vrensen GF, Schlingemann RO: VEGFR-3 in adult angiogenesis. J Pathol 2001, 195:490-497.
24. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, Murray JC: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002, 62:1669-1675.
25. Kern A, Taubert H, Scheele J, Rudroff C, Mothes H, Kappler M, Bartel F, Richter KK: Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. Int J Oncol 2002, 21:243-249.
26. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55:3964-3968.
27. Wendum D, Boelle PY, Rigau V, Sebbagh N, Olschwang S, Mourra N, Parc R, Trugnan G, Masliah J, Flejou JF: Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression. Virchows Arch 2003, 442:111-117.
28. Furudoi A, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Chayama K, Shimamoto F: Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 2002, 62:157-166.
29. Bossi P, Viale G, Lee AK, Alfano R, Coggi G, Bosari S: Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 1995, 55:5049-5053.
30. Fox SH, Whalen GF, Sanders MM, Burleson JA, Jennings K, Kurtzman S, Kreutzer D: Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol 1998, 69:230-234.
31. Rmali KA, Puntis MC, Jiang WG: Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J Gastroenterol 2005, 11:1283-1286.
32. Kondo Y, Arii S, Furutani M, Isigami S, Mori A, Onodera H, Chiba T, Imamura M: Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 2000, 88:1820-1827.
33. Sharma RA, Dalgleish AG, Steward WP, O'Byrne KJ: Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncol Rep 2003, 10:1625-1631.
34. Choi HJ, Hyun MS, Jung GJ, Kim SS, Hong SH: Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 1998, 55:575-581.
35. Onogawa S, Tanaka S, Oka S, Morihara M, Kitadai Y, Sumii M, Yoshihara M, Shimamoto F, Haruma K, Chayama K: Clinical significance of angiogenesis in rectal carcinoid tumors. Oncol Rep 2002, 9:489-494.
36. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T: Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996, 78:226-231.
37. Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F, Van Marck E, Hubens G, Dirix LY: Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999, 79:316-322.
38. Acikalin MF, Oner U, Topcu I, Yasar B, Kiper H, Colak E: Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis 2005, 37:162-169.
39. Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N, O'Malley FP: Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996, 20:1260-1265.
40. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB: Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995, 222:695-699.
41. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL, Tumour and Angiogenesis Research Group: Tumour and Angiogenesis Research Group. Inclusion of vasculature-related variables in the Dukes staging system of colon cancer. Clin Cancer Res 2005, 11:8653-8660.
42. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, Papadimitriou C, Georgoulias V, Gatter KC, Harris AL, Koukourakis MI: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999, 86:1421-1430.
43. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003, 88:1424-1431.
44. Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, Hoefler G, Klimpfinger M, Denk H, Zatloukal K: Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch 2004, 445:160-167.
45. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160:985-1000.
46. Witmer AN, van Blijswijk BC, van Noorden CJ, Vrensen GF, Schlingemann RO: In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J Histochem Cytochem 2004, 52:39-52.
47. Galindo-Gallego M, Fernandez Acenero MJ, Sanz Ortega J, Aljama A: Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J Cancer 2000, 36:55-60.
48. Gunther K, Radkow T, Reymond MA, Pfluger R, Dimmler A, Hohenberger W, Papadopoulos T: Angiogenesis and dendritic cell density are not correlated with metachronous distant metastasis in curatively operated rectal cancer. Int J Colorectal Dis 2003, 18:300-308.
49. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000, 6:4064-4068.
50. Cianchi F, Messerini L, Palomba A, Boddi V, Perigli G, Pucciani F, Bechi P, Cortesini C: Character of the invasive margin in colorectal cancer: does it improve prognostic information of Dukes staging? Dis Colon Rectum 1997, 40:1170-1175.
51. Banner BF, Whitehouse R, Baker SP, Swanson RS: Tumor angiogenesis in stage II colorectal carcinoma: association with survival. Am J Clin Pathol 1998, 109:733-737.
52. Galindo-Gallego M, Fernandez-Acenero MJ, Sanz-Ortega J, Aljama A, Lopez-Elzaurdia C: Prognostic significance of microvascular counts in rectal carcinoma. Pathol Res Pract 2000, 196:607-612.
53. Tarta C, Teixeira CR, Tanaka S, Haruma K, Chiele-Neto C, da Silva VD: Angiogenesis in advanced colorectal adenocarcinoma with special reference to tumoral invasion. Arq Gastroenterol 2002, 39:32-38.
54. Shan YS, Lee JC, Chow NH, Yang HB, Wang ST: Immunohistochemical microvessel count is not a reliable prognostic predictor in colorectal carcinoma. Hepatogastroenterology 2003, 50:1316-1320.
55. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM: Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003, 97:960-968.
56. Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ: Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer 2004, 112:554-559.
57. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal PA Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the uppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
58. Kockar C, Kockar O, Ozturk M, Dagli M, Baybek N, Kosar A: Global fibrinolytic capacity increased exponentially in metastatic colorectal cancer. Clin Appl Thrombosis/Hemostasis 2005, 11:227-230.
59. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H: Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today 1998, 28:373-378.
60. Oya M, Akiyama Y, Okuyama T, Ishikawa H: High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001, 31:388-394.
61. Caine GJ, Stonelake PS, Lip GY, Kehoe ST: The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002, 4:465-473.
62. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV: Vascular endothelial growth factor messenger rna expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 2006, 12:29-33.
63. Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y, Sugimachi K: Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000, 83:887-891.
64. Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, Chayama K: Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003, 64:61-73.
65. Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C: Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998, 78:765-770.
66. Ono T, Miki C: Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma. Am J Gastroenterol 2000, 95: 1062-1067.
67. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, Nakamura M: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998, 77:998-1002.
68. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, Muretto P, Catalano G: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000, 6:2803-2807.
69. Wang TB, Huang YH, Lan P, Song XM, Wang JP: Correlation of lymphangiogenesis to progression of colorectal cancer. Ai Zheng 2005, 24:1276-1279.
70. Byrne AM, Bouchier-Hayes DJ, Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005, 9:777-794.
71. Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001, 114:853-865.
72. Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP: Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 1998, 29:910-914.
73. Okamoto K, Oshika Y, Fukushima Y, Ohnishi Y, Tokunaga T, Tomii T, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N, Nakumura M: Xenografts of human solid tumors frequently express cellular-associated isoform of vascular endothelial growth factor (VEGF) 189. Oncol Rep 1999, 6:1201-1204.
74. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002, 62:4123-4131.
75. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO: VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004, 64:7822-7835.
76. Fogt F. Zimmerman RL, Ross HM, Daly T, Gausas RE: Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2-40. Oncol Rep 2004, 11:47-50.
77. Kuroyama S, Kobayashi N, Ohbu M, Ohtani Y, Okayasu I, Kakita A: Enzyme histochemical analysis of lymphatic vessels in colon carcinoma: occurrence of lymphangiogenesis within the tumor. Hepatogastroenterology 2005, 52:1057-1061.
78. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002 296:1883-1886.
79. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198.
80. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-191.
81. Medzhitov R, Janeway C Jr: Innate immunity. N Engl J Med 2000, 343:338-344.
82. Benjamini E, Wan AM, Langton BC, Andria ML: Cell activation and immunogenicity. Dev Biol Stand 1986, 63:29-39.
83. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G: Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003, 46:33-57.
84. Fossum B, Gedde-Dahl T 3rd, Breivik J, Eriksen JA, Spurkland A, Thorsby E, Gaudernack G: p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly - >Asp). Int J Cancer 1994, 56:40-45.
85. Maeta M, Saito H, Kondo A. Yamashiro, H, Tsujitani S, Ikeguchi M, Kaibara N: Effects of super-extended paraaortic lymphadenectomy (PAL) on biological responses in totally gastrectomized patients with T3 or T4 gastric cancer. Gastric Cancer 1998, 1:57-63.
86. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357:539-545.
87. Henry F, Bretaudeau L, Barbieux I, Meflah K, Gregoire M: Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells. Res Immunol 1998, 149:673-679.
88. Kaattari S, Scibienski RJ, Benjamini E: The immunoregulatory role of antigen-antibody complexes. I. Assessment of B and T-cell responses. Immunology 1980, 40:9-16.
89. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, Makinen MJ: Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005, 41:2645-2654.
90. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:1767-811.
91. Dabbous MK, North SM, Haney L, Tipton DA, Nicolson GL: Effects of mast cell-macrophage interactions on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts. Clin Exp Metastasis 1995, 13:33-41.
92. Dimitriadou V, Koutsilieris M: Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res 1997, 17:1541-1549.
93. Meininger CJ: Mast cells and tumor-associated angiogenesis. Chem Immunol 1995, 62:239-257.
94. Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M: Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000, 6:3545-3551.
95. Adachi Y, Mori M, Kuroiwa S, Sugimachi K, Enjoji M: Histopathological evaluation of survival time in patients with colorectal carcinoma. J Surg Oncol 1989, 42:219-224.
96. Ali AA, McMillan DC, Matalka II, McNicol AM, McArdle CS: Tumour T-lymphocyte subset infiltration and tumour recurrence following curative resection for colorectal cancer. Eur J Surg Oncol 2004, 30:292-295.
97. Canna K. McArdle PA, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005, 92:651-654.
98. Carlon CA, Fabris G, Arslan-Pagnini C, Pluchinotta AM, Chinelli E, Carniato S: Prognostic correlations of operable carcinoma of the rectum. Dis Colon Rectum 1985, 28:47-50.
99. Di Giorgio A, Botti C, Tocchi A, Mingazzini P, Flammia M: The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int Surg 1992, 77:256-260.
100. Funada Y, Noguchi T, Kikuchi R, Takeno S. Uchida Y, Gabbert HE: Prognostic significance of CD8+ T cell and macrophage peritumoral infittration in colorectal cancer. Oncol Rep 2003, 10:309-313.
101. Harrison JC, Dean FJ, el-Zeky F, Vander Zwaag R: From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pothol 1994, 25:498-505.
102. Murray D, Hreno A, Dutton J, Hampson LG: Prognosis in colon cancer: a pathologic reassessment. Arch Surg 1975, 110:908-913.
103. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH: Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study. BMC Cancer 2001, 1:7.
104. Spratt JS Jr, Spjut HJ: Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer 1967, 20:1976-1985.
105. Svennevig JL, Lunde OC, Holter J, Bjorgsvik D: Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984, 49:375-377.
106. Zhou XG, Yu BM, Shen YX: Surgical treatment and late results in 1226 cases of colorectal cancer. Dis Colon Rectum 1983, 26:250-256.
107. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A. Saez MA, Vallejo C, Martos JA, Moreno M: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79:2320-2328.
108. Diez M, Pollan M, Enriquez JM, Dominguez P, Santana A, Tobaruela E, Muguerza JM, Arrieta F, Rodriguez A, Ruiz A: Histopathologic prognostic score in colorectal adenocarcinomas. Anticancer Res 1998, 18:689-694.
109. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A: Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000, 88:1544-1548.
110. Gao JF, Arbman G, Wadhra TI, Zhang H, Sun XF: Relationships of tumor inflammatory infiltration and necrosis with microsatellite instability in colorectal cancers. World J Gastroenterol 2005, 11:2179-2183.
111. Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RR, Fazio VW: Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 1992, 70:2602-2609.
112. Jass JR: Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986, 39:585-589.
113. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE: Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer 2003, 105:717-723.
114. Menon AG, Janssen-van Rhijn CM, Morreau H. Putter H. Tollenaar RA, van de Velde CJ, Fleuren GJ, Kuppen PJ: Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004, 84:493-501.
115. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F: Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999, 189:487-495.
116. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM: Prognostic value of tumour-inflitrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997, 182:318-324.
117. Watt AG, House AK: Colonic carcinoma: a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis. Cancer 1978, 41:279-282.
118. Cianchi F, Palomba A, Messerini L, Boddi V, Asirelli G, Perigli G. Bechi P, Taddei A, Pucciani F, Cortesini C: Tumor angiogenesis in lymph node-negative rectal cancer: correlation with clinicopathological parameters and prognosis. Ann Surg Oncol 2002, 9:20-26.
119. Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T. Moriya Y: Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol 2003, 84:127-131.
120. Wallin Å Svanvik J, Adell G, Sun XF: Expression of PRL proteins at the margin of rectal cancers in relation to preoperative radiotherapy. Int J Radiat Oncol Biol Phys in press.
121. Dundas SA, Laing RW, O'Cathain A, Seddon I, Slater DN, Stephenson TJ, Underwood JC: Feasibility of new prognostic classification for rectal cancer. J Clin Pathol 1988, 41:1273-1276.
122. Ohtani H, Naito Y, Saito K, Nagura H: Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity? Lab Invest 1997, 77:231-241.
123. Sugita J, Ohtani H, Mizoi T, Saito K. Shiiba K, Sasaki I, Matsuno S, Yagita H, Miyazawa M, Nagura H: Close Association between Fas Ligand (FasL; CD95L)-positive Tumor-associated Macrophages and Apoptotic Cancer Cells along Invasive Margin of Colorectal Carcinoma: A Proposal on Tumor-Host Interactions. Jpn J Cancer Res 2002, 93:320-328.
124. Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ: Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 2005. 11:1210-1214.
125. Oberg A, Samii S, Stenling R, Lindmark G: Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis 2002, 17:25-29.
126. Miyagawa S, Miwa S, Soeda J, Kobayashi A, Kawasaki S: Morphometric analysis of liver macrophages in patients with colorectal liver metastasis. Clin Exp Metastasis 2002, 19:119-125.
127. Nakayama Y, Nagashima N, Minagawa N, Inoue Y, Katsuki T, Onitsuka K, Sako T, Hirata K, Nagara N, Itoh H: Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 2002, 22:4291-6429.
128. Della Porta M, Danova M, Rigolin GM, Brugnatelli S, Rovati B, Tronconi C, Fraulini C, Russo Rossi A, Riccardi A, Castoldi G: Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 2005, 68:276-284.
129. Banner BF, Sonmez-Alpan E, Yousem SA: An immunophenotypic study of the inflammatory cell populations in colon adenomas and carcinomas. Mod Pathol 1993, 6:295-301.
130. Schwaab T, Weiss JE, Schned AR, Barth RJ Jr: Dendritic cell infiltration in colon cancer. J Immunother 2001, 24:130-137.
131. Ambe K, Mori M, Enjoji M: S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989, 63:496-503.
132. Suzuki A, Masuda A. Nagata H, Kameoka S, Kikawada Y, Yamakawa M, Kasajima T: Mature dendritic cells make dusters with T cells in the invasive margin of colorectal carcinoma. J Pathol 2002, 196:37-43.
133. Miyagawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T: Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 2004, 35:1392-1396.
134. Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn C, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ: Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother 2004, 53:978-986.
135. Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, Ferrari-Bravo A, Ferrante R, Vigore L. Rovelli F, Mandala M, Viviani S, Fumagalli L, Gardani GS: Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-I. J Biol Regul Hameost Agents 2001, 15:140-144.
136. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadal S, Kavanaugh D, Carbone DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103.
137. Inoue Y, Nakayama Y, Minagawa N, Katsuki T, Nagashima N, Matsumoto K, Shibao K, Tsurudome Y, Hirata, K, Nagata N, Itoh H: Relationship between interleukin-12-expressing cells and antigen-presenting cells in patients with collorectal cancer. Anticancer Res 2005, 25:3541-3546.
138. Nakayama Y, Inoue Y, Minagawa N, Katsuki T, Nagashima N, Onitsuka K, Tsurudome Y, Sako T, Hirata K, Nagata N, Itoh H: Relationships between S-100 protein-positive cells and clinicapathological factors in patients with colorectal cancer. Anticancer Res 2003, 23:4423-4426.
139. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn CM, Ensink NG, Tollenaar RA. van de Velde CJ, Kuppen PJ: Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005, 11:2576-2582.
140. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
141. Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino, M, Goicoechea S, McDonald JA. Dedhar S: Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem 1998, 273:528-536.
142. Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, de Herreros AG, Dedhar S: Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/-human colon carcinoma cells. Oncogene 2001, 20:133-140.
143. Burridge K, Chrzanowska-Wodnicka M: Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 1996, 12:463-518.
144. Varani J: Interaction of tumor cells with the extracellular matrix. Revis Biol Celular 1987, 12:1-113.
145. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003, 253:269-285.
146. Momohara S, Okamoto H, Komiya K, Ikari K, Takeuchi M, Tomatsu T, Kamatani N: Matrix metalloproteinase 28/epilysin expression in cartilage from patients with rheumatoid arthritis and osteoarthritis: comment on the article by Kevorkian et al. Arthritis Rheum 2004, 50:131-141.
147. Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996, 7:147-154.
148. Lukashev ME, Werb Z: ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 1998, 8:437-441.
149. Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K, Koono M: Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alphal-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am J Pathol 1999, 154:457-468.
150. Gorelik L, Flavell RA: Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001, 7:1118-1122.
151. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
152. Yamamoto H, Horiuchi S, Adachi Y, Taniguchi H, Nosho K, Min Y, Imai K: Expression of ets-related transcriptional factor EIAF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis 2004, 25:325-332.
153. Ala-aho R, Grenman R, Seth P, Kahari VM: Adenoviral delivery of p55 gene suppresses expression of conagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene 2002, 21:1187-1195.
154. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD, Howell DS, Cheung HS: Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 2000, 275:11327-11332.
155. Baker EA, Bergin FG, Leaper DJ: Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 2000, 87:1215-1221.
156. Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M, Florin A. Wernert N: Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 2003, 107:183-188.
157. Chan CC, Menges M, Orzechowski HD, Orendain N, Pistorius G, Feifel G, Zeitz M, Stallmach A: Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis 2001, 16:133-140.
158. Garbert EA, Reed MW, Brown NJ: Proteolysis in colorectal cancer. Mol Pathol 1999, 52:140-145.
159. Islekel H, Oktay G, Terzi C, Canda AE. Fuzun M, Kupelioglu A: Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectall cancer: relationship to clinicopathological variables. Cell Biochem Funct 2006 in press.
160. Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A. Papakonstantinou E, Vretou E, Mirtsou-Fidani V: Increased type IV collagendegrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 1997, 17:158-168.
161. Langenskiold M, Holmdahl L, Falk P, Ivarsson ML: Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis 2005, 20:245-252.
162. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996, 56:190-196.
163. Luo HZ, Zhou ZG, Yang L, Yu YY, Tian C, Zhou B, Zheng XL, Xia QJ, Li Y, Wang R: Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn J Clin Oncol 2005, 35:739-744.
164. Parsons SL, Watson SA, Collins HM, Griffin NP, Clarke PA, Steele RJ: Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 1998, 78:1495-1502.
165. Roeb E, Arndt M, Jansen B, Schumpelick V, Matern S: Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and - 13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis 2004, 19:518-524.
166. Saitoh Y, Yanai H, Higaki S, Nohara H, Yoshida T, Okita K: Relationship between matrix metalonproteinase-7 and anti pit pattern in early stage colorectal cancer. Gastrointest Endosc 2004, 59:385-392.
167. Zeng ZS, Shu WP, Cohen AM, Guillem JG: Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 2002, 8:144-148.
168. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. In Vivo 2000, 14:659-666.
169. Bister VO, Salmela MT, Kirjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, Lopez-Otin C, Saarialho-Kere U: Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci 2004, 49:653-661.
170. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996, 2:461-462.
171. Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G: Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumour stage. Br J Cancer 1997, 76:805-811.
172. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H: Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 1997, 88:72-81.
173. Masaki T, Matsuoka H, Sugjyama M, Abe N, Goto A, Sakamoto A, Atomi Y: Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001, 84:1317-1321.
174. Ogawa M, Ikeuchi K, Watanabe M, Etoh K, Kobayashi T, Takao Y, Anazawa S, Yamazaki Y: Expression of matrix metalloproteinase 7, laminin and type IV collagen-associated liver metastasis in human colorectal cancer: immunchistochemical approach. Hepatogastroenterology 2005, 52:875-880.
175. Leeman MF, McKay JA, Murray GI: Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002, 55:758-762.
176. Patterson BC, Sang QA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997, 272:28823-28825.
177. O'Reilly MS, Wiederschain D. Stetler-Stevenson WG, Folkman J, Moses MA: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999, 274:29568-29571.
178. Skoglund J, Emterling A, Arbman G. Anglard P, Sun XF: Clinicopathological significance of stromelysin-3 expression in colorectal cancer. Oncology 2004, 67:67-72.
179. Gao J, Arbman G, Rearden A. Sun XF: Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia 2004, 6:796-801.
180. Levy A, Zucman J, Delattre O. Mattei MG, Rio MC, Basset P: Assignment of the human stromelysin 3 (STMY3) gene to the q11.2 region of chromosome 22. Genomics 1992, 13:881-883.
181. Anglard P, Melot T, Guerin E, Thomas G, Basset P: Structure and promoter characterization of the human stromelysin-3 gene. J Biol Chem 1995, 270:20337-20344.
182. Basset P, Wolf C, Chambon P: Expression of the Stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat 1993, 24:185-193.
183. Pei D, Weiss SJ: Furin-dependant intracellular activation of the human Stromelysin-3 zymogen. Nature 1995, 375:244-247.
184. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
185. Manes S, Mira E, Barbacid MM, Cipres A. Fernandez-Resa P, Buesa JM, Merida I, Aracil M, Marquez G, Martinez-A C: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997, 272:25706-25712.
186. Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautes-Fridman C, Basset P, Rio MC: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 2001, 61:2189-2193.
187. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T, Ochiai A: Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 2004, 64:665-671.
188. Soni S, Mathur M, Shukla NK, Deo SV, Ralhan R: Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer 2003, 107:309-316.
189. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C: Neoplastic progression of human colorectal cancer is associated with over expression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995, 64:70-75.
190. Thewes M, Pohlmann G, Atkinson M, Mueller J, Putz B, Hofler H: Stromelysin-3 (ST3) mRNA expression in colorectal carcinomas. Diagn Mol Pathol 1996, 5:284-290.
191. Urbanski SJ, Edwards DR, Hershfield N, Huchcroft SA, Shaffer E, Sutherland L, Kossakowska AE: Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol 1993, 2:81-89.
192. Wlodarczyk J, Bethke B, Mueller E, Stolte M, Mueller J: A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum. Virchows Arch 2001, 439:756-761.
193. Rouyer N, Wolf C, Chenard M, Rio MC, Chambon P, Bellocq JP, Basset P: Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 1995, 14:1994-269.
194. Mueller J, Mueller E, Arras E, Bethke B, Stolte M, Hofler H: Stromelysin-3 expression in early (pTI) carcinomas and pseudoinvasive lesions of the colorectum. Virchows Arch 1997, 430:213-219.
195. Rearden A: A new LIM protein containing an autoepitope homologous to "senescent cell antigen". Biochem Biophys Res Commun 1994, 201:1124-1131.
196. Dougherty GW, Chopp T, Qi SM, Cutler ML: The Ras suppressor Rsu-1 binds to the LIM 5 domain of the adaptor protein PINCH1 and participates in adhesion-related functions. Exp Cell Res 2005, 306:168-179.
197. Tu Y, Li F, Wu C: Nck-2, a novel Src homology2/3-containing adaptor protein that interacts with the LIM-only protein PINCH and components of growth factor receptor kinase-signaling pathways. Mol Biol Cell 1998. 9:3367-3382.
198. Tu Y, Li F, Goicoechea S, Wu C: The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol 1999, 19:2425-2434.
199. Hobert O, Moerman DG, Clark KA, Beckerle MC, Ruvkun G: A conserved LIM protein that affects muscular adherens junction integrity and mechanosensory function in Caenorhabditis elegans. J Cell Biol 1999, 144:45-57.
200. Braun A, Bordoy R, Stanchi F, Moser M, Kostka GG, Ehler E, Brandau O, Fassler R: PINCH2 is a new five LIM domain protein, homologous to PINCHand localized to focal adhesions. Exp Cell Res 2003, 284:239-250.
201. Dawid IB, Breen JJ. Toyama R: LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet 1998, 14:156-162.
202. Jurata LW, Gill GN: Structure and function of LIM domains. Curr Top Microbiol Immunol 1998, 228:75-113.
203. Tu Y, Huang Y, Zhang Y, Hua Y, Wu C: A new focal adhesion protein that interacts with integrin-linked kinase and regulates cell adhesion and spreading. J Cell Biol 2001, 153:585-598.
204. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC, Dedhar S: Regulation of cell adhesion and anchorage-dependent growth by a new beta I-integrin-linked protein kinase. Nature 1996, 379:91-96.
205. Yamaji S, Suzuki A, Sugiyama Y, Koide Y, Yoshida M, Kanamori H, Mohri H, Ohno S, Ishigatsubo Y: A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction. J Cell Biol 2001, 153:1251-164.
206. Zhang Y, Chen K, Tu Y, Wu C: Distinct roles of two structurally closely related focal adhesion proteins, alpha-parvins and beta-parvins, in regulation of cell morphology and survival. J Biol Chem 2004, 279:41695-41705.
207. Turner CE, Glenney JR Jr, Burridge K: Paxillin. a new vinculin binding protein present in focal adhesions. J Cell Biol 1990, 111:1059-1068.
208. Zhang Y, Chen K, Guo L, Wu C: Characterization of PINCH-2, a new focal adhesion protein that regulates the PINCH-1-ILK interaction, cell spreading, and migration. J Biol Chem 2002, 277:38328-38338.
209. Zhang Y, Guo L. Chen K, Wu C: A critical role of the PINCH-integrin-linked kinase interaction in the regulation of cell shape change and migration. J Biol Chem 2002, 277:318-326.
210. Guo L, Wu C: Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex. FASEB J 2002, 16:1298-1300.
211. Wang-Rodriguez J, Dreilinger AD, Alsharabi GM, Rearden A: The signaling adapter protein PINCH is upregulated in the stroma of common cancers, notably at invasion edges. Cancer 2002, 95:1387-1395.
212. Zhao ZR, Zhang ZY, Cui DS, Jiang L, Zhang HJ, Wang MW, Sun XF: PINCH expression in colorectal adenocarcinoma. World J Gastroenterol 2006, 14, 12:298-301.
213. Lieubeau B, Heymann MF, Henry F, Barbieux I, Meflah K, Gregoire M: Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development. Int J Cancer 1999, 81:629-636.
214. Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer-Hofer K: Isolation and characterization of a scFv antibody specific for tumor endothelial marker I (TEMI). a new reagent for targeted tumor therapy. Cancer Lett 2006, 235:298-308.
215. Gille J: Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 2006, 5:175-186.
216. Van Cutsem E: Progress With biological agents in metastatic colorectal cancer leads to many challenges. J Clin Oncol 2006, 24:3325-3327.
217. Bovo G, Brivio F, Brenna A, Fumagalli L, Perego P, Brivio O, Uggeri F, Lavorato F, Bratina G: Pre-operative interleukin-2 immunotherapy induces easinophilic infiltration in colorectal neoplastic stroma. Pathologica 1995, 87:135-138.
218. Monden T, Morimoto H, Shimano T, Yagyu T, Murotani M, Nagaoka H, Kawasaki Y, Kobayashi T, Mori T: Use of fibrinogen to enhance the antitumor effect of OK-432. A new approach to immunotherapy for colorectal carcinoma. Cancer 1992, 69:636-642.
219. Zucker S. Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004, 23:101-117.
220. Ogata Y, Matono K, Sasatomi T, Ishibashi N, Ohkita A, Mizobe T, Ogo S, Ikeda S, Ozasa H, Shirouzu K: The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol 2006, 57:577-583.